RxDoctor Payments Data

Barbara Galligan, MD

Internal Medicine · Sacramento, CANPI 1679896013

Payments from drug & device makers

$998,211in general payments, 2019–2025

Across 220 payments — averaging $4537.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biontech SE$942K
  • Merck$56K
  • Pfizer$294
  • Medtronic$35
  • E.r. Squibb & Sons, L.L.C.$25
  • AbbVie$16
  • plus $41 from 3 others

What the payments were for

  • Food & beverage$10526%
  • Education$30674%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$998,211 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$2,716,064
Medicare patients
323
Services billed
121,196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate25$432,713
PromactaEltrombopag Olamine15$259,460
LenvimaLenvatinib Mesylate11$257,826
XtandiEnzalutamide15$162,708
CreonLipase/Protease/Amylase15$55,777
EliquisApixaban29$44,342
Letrozole35$2,276
Imatinib Mesylate11$886
Hydroxyurea31$652
Ondansetron OdtOndansetron16$438
Ondansetron Hcl40$409
Anastrozole20$409
Prednisolone Acetate11$356
Prochlorperazine Maleate31$347
Dexamethasone21$335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$16$55,77715 claims
PfizerEliquis$294$44,34229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →